Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
The sale has been approved by the boards of directors of Alpharma and Actavis Group and is expected to close in the fourth quarter of 2005, pending regulatory and other customary approvals. Based upon preliminary estimates, Alpharma believes this transaction is accretive to the company's 2006 planned earnings assuming no transaction.
The company is retaining ownership of its Branded Pharmaceuticals, Active Pharmaceutical Ingredients, and Animal Health businesses, as well as ParMed Pharmaceuticals,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly